2023
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder P, Ellenberg S, Travison T, Brock G, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Tenover J, Tan H, Ho Chee Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Skovsager Andersen M, Velling Magnussen L, Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. The Lancet Healthy Longevity 2023, 4: e561-e572. PMID: 37804846, DOI: 10.1016/s2666-7568(23)00169-1.Peer-Reviewed Original ResearchConceptsBenefits of testosterone treatmentData meta-analysisParticipant data meta-analysisSerum total testosteroneBaseline serum total testosteroneMild erectile dysfunctionTestosterone treatmentParticipant dataMeta-analysisPatient ageIIEF-15Sexual functionTotal testosteroneErectile dysfunctionSymptomatic benefitLow testosteroneSerum total testosterone concentrationsAging Male Symptoms ScoreSystematic reviewBaseline serum testosteroneHealth Technology Assessment programmeOlder menIIEF-15 scoreTestosterone replacement therapyMinimal clinically important difference
2019
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis
Tan W, Trinh Q, Hayn M, Marchese M, Lipsitz S, Nabi J, Kilbridge K, Vale J, Khoubehi B, Kibel A, Sun M, Chang S, Sammon J. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology Seminars And Original Investigations 2019, 38: 74.e13-74.e20. PMID: 31864937, DOI: 10.1016/j.urolonc.2019.11.008.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCT1a renal cell carcinomaImmediate nephrectomyKaplan-Meier curvesOverall survivalCell carcinomaSurgical resectionRenal massesPatient ageTreatment armsCharlson Comorbidity Index 0Compare OS of patientsLong-term overall survivalInfluence of patient ageCox proportional hazards regression analysisEarly surgical resectionLong-term OSMedian patient ageProportional hazards regression analysisMedian follow-upNational Cancer DatabaseOS of patientsSmall renal massesInverse probabilityRecommended treatment optionDevelopment and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Tan W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J, Khetrapal P, Baker H, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Watson D, Knight H, Maher S, Rane A, Pathmanathan B, Harmathova A, Hellawell G, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann A, Cook J, Cornwell M, Mills R, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Gupwell K, Whiteley S, Brown A, McGrath J, Lunt N, Hill P, Sinclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Davies M, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, Speed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Rees A, Williams S, Dukes S, Goffe A, Dawson L, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Payne D, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K, Sarpong R, Brew‐Graves C, Williams N. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal Of Internal Medicine 2019, 285: 436-445. PMID: 30521125, PMCID: PMC6446724, DOI: 10.1111/joim.12868.Peer-Reviewed Original ResearchConceptsCancer risk scoreNational Institute for Health and Clinical Excellence guidelinesRisk scoreInvestigation of haematuriaPhysician decision-makingAge-specific thresholdsValidation cohortExcellence guidelinesUK hospitalsAmerican Urological Association guidelinesNational guidelinesImprove patientNo significant overfittingImprove patient selectionUpper tract cancerLack of consensusAssociation guidelinesSmoking historySwiss patientsCohortPatient ageDevelopment cohortPatient selectionGuidelinesHaematuria